Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2023-08-09 Interim / Quarterly Rep…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2023
2023-08-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2023, by ADMA Biologics, Inc. It announces the issuance of a press release containing financial results for the quarter ended June 30, 2023, and a business update. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length of the document is 3425 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the results themselves. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results.
2023-08-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 19, 2023. It announces FDA approval of a plasma collection facility and includes a press release as an exhibit. The content is an event announcement rather than a full financial report or detailed management discussion. The document length is 3323 characters, which is relatively short and mainly serves to notify the market of a specific event. There are no financial statements or detailed financial analysis present. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-07-19 English
Director's Dealing 2023
Director's Dealing
2023-07-06 English
Director's Dealing 2023
Director's Dealing
2023-07-06 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 6, 2023, reporting the submission of matters to a vote of security holders at the company's 2023 Annual Meeting of Stockholders. It details the voting results for the election of a Class I director and the ratification of the appointment of the independent registered public accounting firm. The content focuses on official voting results from the shareholder meeting, including vote counts and outcomes. There is no detailed financial report or management discussion, but rather the official announcement of voting results. According to the filing definitions, this matches the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is 4562 characters, which is sufficient to contain detailed voting results, not just a brief announcement. Therefore, the correct classification is DVA with high confidence.
2023-06-06 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.